Lentiviral vectors for the preparation of immunotherapeutical compositions
US7968332B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 6, 2002 |
| Grant date | Jun 28, 2011 |
| Priority date | — |
| Expiry date | Jun 20, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/203
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.